

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

In the Description

At page 91, line 11 to page 92, line 2, please delete the paragraphs corresponding to Examples 14, 14a and 15.

At page 100, line 9, immediately above "Assay Protocols", please add the following compounds to the list of compounds:-

1-(Indole-6-carbonyl-D-phenylglyciny1)-4-[(R)-(3-hydroxy-methylpyrrolidin-1-yl)methyl]piperidine Trifluoroacetate Salt

1-(Indole-6-carbonyl-D-phenylglyciny1)-4-[(R)-(3-hydroxy-methylpyrrolidin-1-yl)methyl]piperidine Hydrochloride Salt

1-(Indole-6-carbonyl-D-phenylglyciny1)-4-[(S)-(3-hydroxy-methylpyrrolidin-1-yl)methyl]piperidine Trifluoroacetate Salt

In the Claims


Please cancel Claims 14, 15, 22, 23, 25 and 26 (without prejudice); enter the indicated amendments to Claims 3 to 8, 10 to 13, 16 to 21; and enter new Claims 27-31. Directions for amendment of claims are indicated on the copy of the attached hand amended ("marked up") original claims, showing in manuscript the amendments that have been made and the origins of the new claims. Clean forms of new and rewritten claims are included in the attached "Clean Pending Claims" document.

Remarks

This application seeks protection for certain novel compounds that are inhibitors of the serine protease, Factor Xa, and are useful for the treatment of thrombotic disorders. It is the national stage of an international

Clean Set of Claims

1. A serine protease inhibitor compound of formula (I)



(I)

wherein:

R₂ is a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom, optionally being substituted in the 3 and/or 4 position (in relation to the point of attachment of X-X) by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, MeSO₂- or R₁, or the substituents at the 3 and 4 positions taken together form a fused ring which is a 5 or 6 membered carbocyclic or heterocyclic ring optionally substituted by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j}, and optionally substituted in the position alpha to the X-X group (i.e. 6 position for a six membered aromatic ring etc) by amino, hydroxy, halo, alkyl, carboxy, alkoxycarbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio with the proviso that R₂ cannot be aminoisoquinolyl;

each X independently is a C, N, O or S atom or a CO, CR_{1a}, C(R_{1a})₂ or NR_{1a} group, at least one X being C, CO, CR_{1a} or C(R_{1a})₂;

each R_{1a} independently represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

R₁ is as defined for R_{1a}, provided that R₁ is not unsubstituted aminoalkyl;

Y (the α -atom) is a nitrogen atom or a CR_{1b} group;

Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group, optionally substituted by groups R_{3a} or phenyl optionally substituted by R_{3a} or R_{3i}X_i ;


5 each R_{3a} independently is R_{1c} , amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkylimidazolyl, thiazolyl, alkylthiazolyl, alkylloxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a
 10 group of the formula $-\text{C}(\text{X}^3)\text{N}(\text{R}^{11})\text{R}^{12}$ (wherein X^3 is O or S; and R^{11} and R^{12} are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group), or $-\text{OCH}_2\text{O}-$ which is bonded to two adjacent ring atoms
 15 in Cy;

X_i is a bond, O, NH or CH_2 ;

R_{3i} is phenyl, pyridyl or pyrimidinyl optionally substituted by R_{3a} ;

R_{1b} , R_{1c} and R_{1j} are as defined for R_{1a} ; and

20 $-\text{L}-\text{Lp}(\text{D})_n$ is




q is 1 or 2;

Q is methylene; and R_q is NR_aR_b in which each of R_a and R_b independently is hydrogen or C_{1-3} alkyl; or one of R_a and R_b is
 25 hydrogen or methyl and the other of R_a and R_b is (3-
 6C)cycloalkyl, pyrid-4-yl, $-\text{CH}_2-\text{R}_c$ or $-\text{CH}_2-\text{R}_d$ in which R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, CONH_2 , SO_2NH_2 , methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or
 30 methylsulphonyl substituent) and in which R_d is isopropyl or

- cyclopentyl, or NR_aR_b is azetidino, pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino, or tetrahydro-1,4-diazepino [in which a pyrrolidino or piperidino may be a 3,4-didehydro derivative and in which a azetidino,
- 5 pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino, or tetrahydro-1,4-diazepino may be optionally substituted on a ring carbon atom by hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl (provided that the amino,
- 10 hydroxy or alkoxy substituent is not on a ring carbon atom which is included in a double bond, or adjacent to a ring oxygen, sulfur or nitrogen atom) and in which the piperazino or tetrahydro-1,4-diazepino may bear a methyl group at the 4-position];
- 15 or a physiologically-tolerable salt thereof.

2. A compound according to claim 1 wherein $-\text{L-Lp}(\text{D})_n$ is of the formula:



20 wherein:

- q is 1 or 2;
- Q is methylene; and R_q is NR_aR_b in which each of R_a and R_b independently is hydrogen or C_{1-3} alkyl; or one of R_a and R_b is hydrogen or methyl and the other of R_a and R_b is $-\text{CH}_2-\text{R}_c$
- 25 or $-\text{CH}_2-\text{R}_d$ in which R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, CONH_2 , SO_2NH_2 , methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or methylsulphonyl substituent) and in which R_d is isopropyl or cyclopentyl, or NR_aR_b is
- 30 pyrrolidino, piperidino, morpholino, piperazino, or tetrahydro-1,4-diazepino in which a pyrrolidino or piperidino

may be a 3,4-didehydro derivative and in which a pyrrolidino, piperidino, piperazino, or tetrahydro-1,4-diazepino may bear a methyl group at the 4-position;
or a physiologically-tolerable salt thereof.

5

3. (amended) A compound according to claim 1 wherein q is 2.

✓
4. (amended) A compound according to claim 1 wherein
R_q is NR_aR_b in which R_a is hydrogen or C₁₋₃alkyl and R_b is C₁₋₃alkyl; or R_a is hydrogen and R_b is (3-6C)cycloalkyl or pyrid-
10 4-yl; or NR_aR_b is azetidino, pyrrolidino, piperidino, morpholino, thiomorpholino or piperazino [in which a pyrrolidino, piperidino or piperazino may be optionally substituted on a ring carbon atom by hydroxy or hydroxymethyl
15 (provided that the hydroxy substituent is not on a ring carbon atom which is adjacent to a ring nitrogen atom) and in which the piperazino may bear a methyl group at the 4-position].

✓
5. (amended) A compound according to claim 1 wherein R_q is
20 selected from dimethylamino, diethylamino, prop-2-ylamino, pyrrolidino, 3-pyrrolino, 3-hydroxypyrrolidino, 3-hydroxymethylpyrrolidino, piperidino, 3-hydroxypiperidino, 4-hydroxypiperidino, 4-hydroxymethylpiperidino, piperazino and 4-methylpiperazino.

25









✓
6. (amended) A compound according to claim 1 wherein R₂ is phenyl, thien-2-yl, naphthyl, indol-2-yl, indol-6-yl, benzo[b]furan-5-yl, benzo[b]thiophen-2-yl or benzimidazol-2-yl (each of which is optionally substituted as defined in claim
30 1).

✓
7. (amended) A compound according to claim 6 wherein optional substituents for R₂ are selected from:
fluoro, chloro, bromo, iodo, nitro, thiol, difluoromethoxy,

trifluoromethoxy, hydrazido, methylhydrazido, amino, cyano, trifluoromethyl, methylthio, vinyl, ethynyl, acetylamino, carboxy, acetoxy, hydroxy, methyl, ethyl, amido (CONH₂), aminomethyl, methoxy and ethoxy.

5

8. (amended) A compound according to claim 1 wherein R₂ is selected from one of the formula (A') to (H'):



10 wherein X₄ is O or S, R₁₃ is selected from hydrogen, chloro or methyl and R₁₄ is selected from hydrogen, methyl, ethyl, fluoro, chloro, and methoxy and R₁₅ is selected from hydrogen, methyl, fluoro, chloro and amino.

15 9. A compound according to claim 8, wherein R₂ is 4-

methoxyphenyl, 5-chloroindol-2-yl, 3-chloroindol-6-yl, indol-6-yl or 3-methylindol-6-yl.

10. (amended) A compound according to claim 1 wherein -X-X- is
5 -CONH-.

11. (amended) A compound according to any one of claims 1 to 10, 12 to 13 and 16 to 19, wherein Y is CH.

12. (amended) A compound according to claim 1 wherein Cy is an optionally R_{3a} substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl, furanyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, imidazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, pyrimidinyl,
15 pyridazinyl, quinoloyl, isoquinolyl, benzofuryl, benzothienyl or cycloalkyl group, or a phenyl group substituted by R_{3i}X_i in which X_i is a bond, O, NH or CH₂ and R_{3i} is phenyl optionally substituted by R_{3a}.

20 13. (amended) A compound according to claim 1 wherein Cy is an optionally R_{3a} substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl or cycloalkyl group.

14. (cancelled on national phase entry).













25 15. (cancelled on national phase entry).

16. (amended) A compound according to claim 12 wherein R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminomethyl, CONH₂, CH₂CONH₂, acetyl amino, methoxycarbonylamino, ethoxycarbonylamino, t-butoxycarbonylamino, amino, fluoro,


chloro, bromo, cyano, nitro, thiol, methylthio,
methysulphonyl, ethylsulphonyl, methysulphenyl,
methysulphonylamido, ethylsulphonylamido,
methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl,
5 trifluoromethoxy, trifluoromethyl, pyrrolidin-1-ylcarbonyl,
piperidin-1-ylcarbonyl or morpholin-1-ylcarbonyl and -OCH₂O-
(which is bonded to two adjacent ring atoms in Cy).

Q2
17. (amended) A compound according to claim 13 wherein R_{3a} is
10 selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl,
ethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl,
carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl,
methylaminocarbonyl, dimethylaminocarbonyl, aminomethyl,
CONH₂, CH₂CONH₂, acetyl amino, methoxycarbonylamino,
15 ethoxycarbonylamino, t-butoxycarbonylamino, amino, fluoro,
chloro, cyano, nitro, thiol, methylthio, methysulphonyl,
ethylsulphonyl, methysulphenyl, methysulphonylamido,
ethylsulphonylamido, methylaminosulphonyl,
ethylaminosulphonyl, aminosulphonyl, trifluoromethoxy and
20 trifluoromethyl.

18. (amended) A compound according to claim 1 wherein Cy is
selected from:



or



wherein:

X' is selected from O, S and NMe;

5 X'' is selected from O and S;

X''' is selected from O, S, NH and NMe;

Y' is selected from hydrogen, amino and methyl;

R_o is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphinyl and

10 methylsulphonyl;

R_m is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphinyl, methylsulphonyl, carboxy, methoxycarbonyl and a group of the

12
 Conf

formula $-C(X^3)N(R^{11})R^{12}$ (wherein X^3 is O or S, and R^{11} and R^{12} are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group);

5 R_p is selected from hydrogen and fluoro; or

R_o and R_m or R_m and R_p form an $-OCH_2O-$ group; or

R_o and R_m together with the ring to which they are attached form a 5 or 6 membered aryl or heteroaryl ring (wherein the heteroaryl ring contains 1 or 2 heteroatoms selected from


10 nitrogen, oxygen and sulfur); and

one of R_{o1} and R_{o2} is hydrogen and the other is R_o .

19. (amended) A compound according to claim 18 wherein Cy is selected from phenyl, 2-chlorophenyl, 2-methoxyphenyl,

15 4-carbamoylphenyl, pyrid-2-yl, pyrid-4-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, 2-amino-thiazol-4-yl, thiazol-5-yl, naphth-1-yl, isoquinolin-5-yl, isoquinolin-8-yl, quinolin-4-yl, quinolin-5-yl and quinolin-8-yl.

20

 20. (amended) A compound as claimed in Claim 11, in which the alpha atom in Y is carbon and has the conformation that would result from construction from a D- α -aminoacid $NH_2-CR_{1b}(Cy)-COOH$ where the NH_2 represents part of X-X.

25

21. (amended) A pharmaceutical composition, which comprises a compound as claimed in claim 1 together with at least one pharmaceutically acceptable carrier or excipient.

30 22. (cancelled on national phase entry).

23. (cancelled on national phase entry).

24. A method of treatment of a human or non-human animal body









Ad cont
to combat a thrombotic disorder, which comprises administering to said body an effective amount of a compound as claimed in claim 1.

5 25. (cancelled on national phase entry).

26. (cancelled on national phase entry).

27. (new) A compound according to claim 1 wherein:-

10 R_2 is selected from one of the formula (A') to (H'):















wherein X_4 is O or S, R_{13} is selected from hydrogen, chloro or methyl and R_{14} is selected from hydrogen, methyl, ethyl, 15 fluoro, chloro, and methoxy and R_{15} is selected from hydrogen,

methyl, fluoro, chloro and amino;


-X-X- is -CONH-;

Y is CH and has the conformation that would result from construction from a D- α -aminoacid $\text{NH}_2\text{-CR}_{1b}(\text{Cy})\text{-COOH}$ where the 5 NH_2 represents part of X-X;

Cy is selected from



or



10 wherein:

X' is selected from O, S and NMe;

X'' is selected from O and S;

X''' is selected from O, S, NH and NMe;

Y' is selected from hydrogen, amino and methyl;
R_O is selected from hydrogen, methyl, fluoro, chloro,
trifluoromethyl, methoxy, methylthio, methylsulphanyl and
methylsulphonyl;

5 R_m is selected from hydrogen, methyl, fluoro, chloro,
trifluoromethyl, methoxy, methylthio, methylsulphanyl,
methylsulphonyl, carboxy, methoxycarbonyl and a group of the
formula -C(X³)N(R¹¹)R¹² (wherein X³ is O or S, and R¹¹ and R¹² are
independently selected from hydrogen, methyl or ethyl or

10 together with the nitrogen atom to which they are attached
form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group);

R_p is selected from hydrogen and fluoro; or


R_O and R_m or R_m and R_p form an -OCH₂O- group; or

R_O and R_m together with the ring to which they are attached

15 form a 5 or 6 membered aryl or heteroaryl ring (wherein the
heteroaryl ring contains 1 or 2 heteroatoms selected from
nitrogen, oxygen and sulfur); and

one of R_{O1} and R_{O2} is hydrogen and the other is R_O; and

q is 2.

 20
28. (New) A compound according to claim 27 wherein R_q is
selected from dimethylamino, diethylamino, prop-2-ylamino,
pyrrolidino, 3-pyrrolino, 3-hydroxypyrrolidino, 3-
hydroxymethylpyrrolidino, piperidino, 3-hydroxypiperidino, 4-
25 hydroxypiperidino, 4-hydroxymethylpiperidino, piperazino and
4-methylpiperazino.

29. (New) A compound according to Claim 28 wherein R₂ is 4-
methoxyphenyl, 5-chloroindol-2-yl, 3-chloroindol-6-yl, indol-
30 6-yl or 3-methylindol-6-yl.

30. (New) A compound according to claim 29 wherein Cy is
selected from phenyl, 2-chlorophenyl, 2-methoxyphenyl,
4-carbamoylphenyl, pyrid-2-yl, pyrid-4-yl, thien-2-yl, thien-

3-yl, furan-2-yl, furan-3-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, 2-amino-thiazol-4-yl, thiazol-5-yl, naphth-1-yl, isoquinolin-5-yl, isoquinolin-8-yl, quinolin-4-yl, quinolin-5-yl and quinolin-8-yl.

5

31. (New) A compound according to claim 30 wherein Cy is phenyl.

20140223 09:02:00